Associated Papers
Structural Analysis of Janus Tyrosine Kinase Variants in Hematological Malignancies: Implications for Drug Development and Opportunities for Novel Therapeutic Strategies.
Rodriguez Moncivais OJ et al.
International Journal of Molecular Sciences, 2023
Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J et al.
International Journal of Laboratory Hematology, 2021
p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation.
Eder-Azanza L et al.
Haematologica, 2017
Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides.
McGirt LY et al.
Blood, 2015
JAK/STAT signaling in hematological malignancies.
Vainchenker W et al.
Oncogene, 2013
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
23819521 (PubMed )
Supplement: 1471-2164-14-S3-S7-S1.xlsx › COSMIC
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Koo GC et al.
Cancer Discovery, 2012
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
Elliott NE et al.
Blood, 2011
Select a paper to view details